Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
About Nutriband Inc.
Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company headquartered in Oviedo, Florida, specializing in the development and commercialization of innovative transdermal drug delivery systems. The company’s primary focus lies in leveraging its proprietary AVERSA™ abuse-deterrent technology to address critical safety concerns in the pharmaceutical industry, particularly related to opioid medications. By integrating aversive agents into transdermal patches, Nutriband enhances safety by preventing the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.
Core Business and Technology
Nutriband’s flagship product under development is the AVERSA™ Fentanyl transdermal patch, which aims to become the world’s first abuse-deterrent opioid patch. This innovative technology incorporates aversive agents, such as denatonium benzoate (Bitrex®), to create a bitter taste that deters oral abuse and accidental exposure, particularly in children. The AVERSA™ platform technology is versatile and can be applied to other transdermal formulations, broadening its potential applications in the pharmaceutical market.
The company operates within a robust intellectual property framework, with patents granted in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This extensive portfolio underscores Nutriband’s commitment to securing its technological innovations on a global scale.
Revenue Streams and Market Reach
Nutriband generates revenue through multiple channels, including the sale of consumer transdermal and coated products, as well as contract manufacturing services provided by its subsidiary, Pocono Pharma. Pocono Pharma specializes in kinesiology tape manufacturing and serves major retail clients, such as Target, Walmart, Walgreens, and CVS. This diversification not only strengthens Nutriband’s financial foundation but also positions it as a trusted partner in the manufacturing of specialized consumer healthcare products.
Industry Context and Competitive Position
Nutriband operates at the intersection of the pharmaceutical and healthcare industries, addressing critical challenges such as the opioid crisis and medication safety. The company’s AVERSA™ technology aligns with growing regulatory and societal demand for safer drug delivery systems. By focusing on transdermal solutions, Nutriband differentiates itself from competitors that primarily rely on traditional oral or injectable drug formulations. Its partnership with Kindeva Drug Delivery, a leading contract development and manufacturing organization, further enhances its capabilities in scaling and commercializing its products.
Intellectual Property and Global Expansion
With patents issued in major global markets, Nutriband has established a strong foundation for international expansion. Recent advancements include the extension of its intellectual property to regions such as Hong Kong and Macao, further solidifying its presence in Asia. These developments position Nutriband as a leader in the abuse-deterrent pharmaceutical space, capable of addressing both regional and global market needs.
Commitment to Innovation and Patient Safety
At its core, Nutriband is driven by a mission to enhance patient safety through innovative technologies. The AVERSA™ platform not only addresses the risks associated with opioid misuse but also ensures that essential medications remain accessible to patients who need them. This dual focus on safety and accessibility underscores Nutriband’s role as a socially responsible player in the pharmaceutical industry.
Conclusion
In summary, Nutriband Inc. is a pioneering company in the field of transdermal drug delivery, leveraging its proprietary AVERSA™ technology to address pressing healthcare challenges. With a diversified revenue model, strong intellectual property portfolio, and strategic partnerships, Nutriband is well-positioned to make a meaningful impact in the pharmaceutical and healthcare industries.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) endorses the 2022 CDC guidelines on opioid prescribing, emphasizing the need for abuse deterrent technologies in pain management. The new guidelines allow greater opioid access for those with chronic pain while recognizing the challenges of the prior restrictions. Nutriband's AVERSA™ technology aims to mitigate abuse risks associated with transdermal opioids. The lead product, AVERSA™ Fentanyl, is projected to generate $80M - $200M in potential annual sales post-launch, enhancing safety for vulnerable patient groups.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into an exclusive manufacturing agreement with Fleur Marché for CBD and Botanical Patches. Nutriband's subsidiary, Active Intelligence, will be the exclusive manufacturer for these products. Fleur Marché, founded in 2019, focuses on wellness patches aimed at simplifying health solutions for busy consumers. Products are available in retailers such as Bed Bath and Beyond and Nordstrom. This partnership is expected to highlight Nutriband's manufacturing capabilities using innovative technologies.
Nutriband Inc. (NASDAQ:NTRB) announced its subsidiary, 4P Therapeutics, completed a Phase 1b clinical study for Sorrento Therapeutics (NASDAQ:SRNE). Results will be presented at the American College of Rheumatology (ACR) Convergence 2022 on November 13, 2022, highlighting significant improvements in rheumatoid arthritis disease measures at 50% of the standard dose. The study emphasizes the potential of the Sofusa lymphatic delivery platform for treating autoimmune diseases and showcases 4P Therapeutics' capabilities in advancing drug delivery products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has been invited to speak at the 2023 Transdermal and Microneedle Conference in London on January 23-24. CEO Gareth Sheridan will present on improving transdermal technologies to reduce the abuse potential of medications, referencing their AVERSA technology. Additionally, COO Dr. Alan Smith will participate in a panel discussion on microneedles as a drug delivery tool. Other notable participants include representatives from Merck, GSK, and Sanofi.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced progress in collaboration with Kindeva Drug Delivery for their AVERSA™ Fentanyl patch, an abuse-deterrent transdermal system. Recent studies confirm that Nutriband's aversive coating can be produced with standard manufacturing processes, crucial for product development. The product has a projected peak annual sales potential of $80M - $200M within five years post-launch. Nutriband aims to finalize product configuration and transfer technology to Kindeva's commercial facility in California.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has initiated the application process for a dual listing on Upstream, a digital trading app. This move aims to tap into a global investor base, facilitating trades in USDC digital currency and traditional payment methods. CEO Gareth Sheridan emphasized that this listing could enhance shareholder value and liquidity while expanding access to international markets. Approval from MERJ Exchange is pending; however, Nutriband's adherence to NASDAQ standards is sufficient for compliance. The company is known for developing abuse deterrent technologies for pharmaceuticals.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will be featured on the RedChip Money Report airing on Bloomberg TV this Saturday, September 17, at 7 p.m. ET. The interview will highlight various aspects of the company, including expanded patents, commercialization plans, and Q2 revenue results. Chairman & President Serguei Melnik will discuss these developments, which could pique investor interest. Bloomberg TV reaches approximately 73 million homes across the U.S.
Nutriband Inc. (NASDAQ:NTRB) reported significant growth in its Q2 2022 financial results, achieving record quarterly revenue of $0.5 million, a 113% increase year-over-year. Over six months, revenue rose 44%. The company received a favorable court ruling enabling the cancellation of 1.2 million shares, representing 15% of outstanding shares at the time. Nutriband continues to expand its AVERSA™ intellectual property, now protected in 45 countries. However, net loss increased to $1.0 million from $0.5 million year-over-year.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the effective date of a 7:6 forward stock split that took place on August 12, 2022, with a record date of August 15, 2022. Each holder of 6 shares of common stock received 7 shares, with no change to the per-share par value. The stock split will not affect stockholders' equity percentages. Additionally, the exercise price of outstanding warrants will be adjusted to $6.43 per share, corresponding to the stock split ratio. Book-entry holders do not need to take action, while those seeking stock certificates will receive further instructions.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a Notice of Allowance for its patent application from the Canadian Intellectual Property Office. This patent is crucial for the company's AVERSA™ transdermal abuse deterrent technology, enhancing intellectual property protection across North America.
The AVERSA™ technology aims to reduce drug misuse and abuse while ensuring accessibility for patients in need. The lead product, AVERSA™ Fentanyl, is projected to achieve peak annual sales of $80M - $200M. Nutriband's patent portfolio spans multiple countries, bolstering its market position.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc.'s primary focus?
What is AVERSA™ technology?
How does Nutriband generate revenue?
What is the significance of Nutriband's intellectual property portfolio?
Who are Nutriband's strategic partners?
What problem does Nutriband aim to solve?
What is Nutriband's flagship product?
What industries does Nutriband operate in?
